Skip to main content
Psychedex

MDEA

N-ethyl-3,4-methylenedioxyamphetamine

1Provenance card

the boundary, as counts

Sources

268 with DOI

1 strong · 20 moderate · 5 weak

Compilations

12026-05-03T18:14:40.310Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

30last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:32:39.262Z

notice · info card · emergency

Searches

171 with no results

queries and counts on the build

Claims checked

10270 supported

70 supported · 32 not

Correspondence

0received

consent field ships in Phase 4

Edges

298

derivations recorded for this entity

Complete over 26 sources, 1 compilation, and 30 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/mdea/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued info_card
  2. 2026-10-02srcInvestigations on the stereoselectivity of the phase II metabolism of the 3,4-methylenedioxyethylamphetamine (MDEA) metabolites 3,4-dihydroxyethylamphetamine (DHEA) and 4-hydroxy-3-methoxyethylamphetamine (HMEA)
  3. 2026-10-02srcEnantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation
  4. 2026-10-02srcChromatographic and Spectroscopic Methods of Identification for the Side-Chain Regioisomers of 3,4-Methylenedioxyphenethylamines Related to MDEA, MDMMA, and MBDB
  5. 2026-10-02srcThe Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)
  6. 2026-10-02srcThe role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxyethylamphetamine and its single enantiomers
  7. 2026-10-02srcOverview of amphetamine-type stimulant mortality data--UK, 1997-2007.
  8. 2026-10-02srcEntactogens: How the Name for a Novel Class of Psychoactive Agents Originated
  9. 2026-10-02srcInteraction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter
  10. 2026-10-02src3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans
  11. 2026-10-02srcThe acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, 'eve') on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ('ecstasy')
  12. 2026-10-02srcLethal combination of tramadol and multiple drugs affecting serotonin
  13. 2026-10-02srcStereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans
  14. 2026-10-02srcBehavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat
  15. 2026-10-02srcEnantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine
  16. 2026-10-02srcActions of amphetamine derivatives and cathinone at the noradrenaline transporter
  17. 2026-10-02srcMeasurement of 3,4-MDMA and related amines in diagnostic and forensic laboratories
  18. 2026-10-02srcAmphetamines as potential inducers of fatalities: a review in the district of Ghent from 1976-2004
  19. 2026-10-02srcEffects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices
  20. 2026-10-02srcDifferences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens
  21. 2026-10-02src'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA
  22. 2026-10-02srcImmunocytochemical evidence for serotonergic neurotoxicity of N-ethyl-methylenedioxyamphetamine (MDE)
  23. 2026-10-02srcNeuroendocrine and cardiovascular effects of MDE in healthy volunteers
  24. 2026-10-02srcEntactogenic drugs 'ecstasy' (MDMA), 'eve' (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?
  25. 2026-10-02srcQuantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection
  26. 2026-10-02srcLegal status of MDEA
  27. 2026-10-02srcMonoamine releasing agent - MDEA pharmacological data
  28. 2026-09-04issueIssued emergency
  29. 2026-09-04issueIssued info_card
  30. 2026-09-04issueIssued notice
  31. 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  32. 2026-06-04publicationPublication — backfill
  33. 2026-05-03revisionRevision 1
  34. 2026-05-03absenceSearched ClinicalTrials.gov for "MDEA methylenedioxyethylamphetamine MDE" — no results
  35. 2026-05-03genGeneration — pipeline-v5 · with 1 morepipeline-v5
  36. 2026-05-03rungeneration run

The same entries, as forms: six forms.